ClinicalTrials.gg
RecruitingNCT07531732SELFSOCUpdated Apr 15, 2026

Links Between Self-awareness and Sociocognitive Processes in Neurodegenerative Diseases

An observational study in Frontotemporal Dementia, Behavioral Variant and Alzheimer Disease, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
34
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 28 studies in Alzheimer Disease by Assistance Publique - Hôpitaux de Paris — 9 open to participants now, 9 under way, 1 of them phase 3. Alzheimer Disease · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
13th of 14
34 · median 97
Started
2026
with 1 other
Observational
14 of 28
4 open now
Registered
28th of 28
by date

Among the 28 studies in Alzheimer Disease by Assistance Publique - Hôpitaux de Paris, this one is the 13th largest by planned enrollment of the 14 observational ones that give a count, is one of 2 that started in 2026, is one of 14 observational ones, and was the 28th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

9 of the 28 studies in Alzheimer Disease by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Alzheimer Disease by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

This monocentric, non-interventional study (SELFSOC) investigates the relationship between self-awareness and social cognition in patients with behavioral variant frontotemporal dementia (bvFTD) and Alzheimer's disease (AD).

The primary objective is to assess metacognitive efficiency related to social cognitive performance using a computerized facial emotion recognition task combined with confidence judgments. Metacognitive indices (including Mratio) will quantify the correspondence between subjective and objective performance.

Thirty-four participants (17 bvFTD, 17 AD; age 50-80; MMSE ≥20) will complete two study visits involving tasks assessing emotion recognition, theory of mind, and memory.

Read the detailed description

Self-awareness impairments are common in neurodegenerative diseases, yet their relationship with social cognition remains poorly understood. This study aims to characterize metacognitive processes associated with social cognition in bvFTD and AD, and to determine whether these processes differ across diagnostic groups.

The primary objective is to evaluate metacognitive efficiency during a facial emotion recognition task using trial-by-trial retrospective confidence judgments, allowing computation of Mratio. This index reflects the alignment between perceived and actual performance.

Secondary objectives include: (1) assessing additional metacognitive measures (prospective and global judgments), (2) comparing metacognition between bvFTD and AD, (3) examining correlations between metacognitive judgments and social cognitive performance, (4) testing domain specificity by comparing social cognition and memory, (5) evaluating the effect of task complexity, (6) assessing the impact of performance feedback, (7) comparing subjective versus objective metacognitive assessments, (8) investigating the role of anosognosia in AD, and (9) exploring associations with hypnotic suggestibility.

Participants will attend two visits (\~2 hours each). The first visit includes eligibility assessment, sociodemographic data collection, and a computerized emotion recognition task with metacognitive judgments. The second visit includes additional computerized tasks assessing theory of mind and memory, and an optional hypnotic suggestibility assessment.

Statistical analyses will include between-group comparisons using non-parametric tests, within-subject analyses, and exploratory correlational and regression analyses.

03

Conditions studied

  • Frontotemporal Dementia, Behavioral Variant
  • Alzheimer Disease

Browse trials for

Keywords

  • Metacognition
  • Social cognition
  • Emotion recognition
  • Theory of Mind
  • Neuropsychology
  • Hypnotic suggestibility
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients diagnosed with behavioral variant frontotemporal lobar degeneration (bvFTD) or Alzheimer's disease (AD) at a mild to moderate stage.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of possible or probable behavioral variant frontotemporal dementia according to the Rascovsky 2011 criteria (DLFTvc group) OR
  • Diagnosis of Alzheimer's disease according to the Jack 2018 criteria, including biomarkers (MA group)
  • (MMSE) ≥ 20
  • Age: 50-80 years
  • Sufficient reading and writing proficiency in French to enable completion of the study procedures, in the investigator's opinion

Exclusion criteria

Exclusion Criteria:

  • Moderate to severe language disorders: Confrontation naming (DO 40 scale) ≤ 32
  • Inability to perform computerized tasks according to the investigator's opinion
  • Other neurological disorders (including epilepsy, Lewy body disease, vascular dementia)
  • Psychiatric comorbidities (bipolar disorder, schizophrenia, current major depressive episode)
  • Uncorrected visual impairment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
34 participants (estimated)
Patient registry
No

Groups and cohorts

  • Behavioral Variant Frontotemporal Dementia (bvFTD)

    Participants diagnosed with behavioral variant frontotemporal dementia according to established clinical criteria (Rascovsky et al., 2011). Patients are aged 50-80 years with mild to moderate disease severity (MMSE ≥20).

    Behavioral: Computer-based facial expression recognition task · Behavioral: Computerized affective task · Behavioral: UCLA Structured Insight Interview · Behavioral: Barber's Standardized Suggestibility Scale

  • Alzheimer's Disease (AD)

    Participants diagnosed with Alzheimer's disease based on biomarker-supported criteria (A+T+; Jack et al., 2018). Patients are aged 50-80 years with mild to moderate disease severity (MMSE ≥20).

    Behavioral: Computer-based facial expression recognition task · Behavioral: Computerized affective task · Behavioral: UCLA Structured Insight Interview · Behavioral: Barber's Standardized Suggestibility Scale

Interventions

  • BehavioralComputer-based facial expression recognition task

    Eighteen facial photographs from the FACES database (Ebner et al., 2010) were selected, each depicting one of six emotions: joy, sadness, disgust, fear, anger, and neutral. For each face, the patient must identify the emotion being expressed by choosing from six verbal labels displayed on the screen.

  • BehavioralComputerized affective task

    The task consists of 32 silent black-and-white videos featuring two characters interacting in a social situation, adapted from the Pierre and Marie task (Caillaud et al., 2020). Each video lasts between 8 and 9 seconds and shows one of the two characters experiencing a specific emotion. Patients will be asked to infer the emotion felt by that character. The emotions depicted are either positive or negative and vary in complexity: embarrassment, pride, anger, and surprise (8 videos for each emotion). After each video, the name of an emotion will appear on the screen, and patients will be asked to indicate whether the displayed emotion matches the one felt by the protagonist (half of the options will be congruent and the other half incongruent). The measured variable will be the rate of correct responses.

  • BehavioralUCLA Structured Insight Interview

    The UCLA Structured Insight Interview (Mendez \& Shapira, 2011), translated into French, will be used to quantify anosognosia. This is a structured interview, conducted by the investigator, designed to assess patients' awareness of their symptoms in cases of neurodegenerative disease.

  • BehavioralBarber's Standardized Suggestibility Scale

    The participant, who must keep their eyes closed throughout the administration of the scale, receives a standardized series of suggestions read aloud by the experimenter in a specific order. These suggestions pertain to motor, sensory, verbal, and mnemonic responses (lowering or raising the arm, clenching the hands, feeling thirsty, speech inhibition, immobility, post-hypnotic response, and amnesia).The scale consists of 8 items and is therefore scored on a scale of 0 to 8 : minimum score 0/8 = no suggestibility; maximum score 8/8 = maximum suggestibility.

06

What researchers measure

Primary outcomes

  1. Metacognitive efficiency during facial emotion recognition (Mratio)

    Metacognitive efficiency (Mratio) derived from a computerized facial emotion recognition task with trial-by-trial retrospective confidence judgments. This measure quantifies the correspondence between subjective confidence and objective performance in social cognition.

    Time frame: Day 0

Secondary outcomes

  1. Prospective and global metacognitive judgments

    Assessment of metacognitive performance using prospective (pre-task) and global (post-task) confidence judgments related to social cognitive tasks.

    Time frame: Day 0, with the second evaluation taking place between Day 1 and Day 20.

  2. Between-group differences in metacognitive efficiency

    Comparison of metacognitive indices (including Mratio) between bvFTD and Alzheimer's disease groups during social cognition tasks.

    Time frame: Day 0, with the second evaluation taking place between Day 1 and Day 20

  3. Association between metacognition and social cognition performance

    Correlation between metacognitive judgments and objective performance on social cognition tasks (emotion recognition and theory of mind).

    Time frame: Day 0, with the second evaluation taking place between Day 1 and Day 20

  4. Domain specificity of metacognition (social cognition vs memory)

    Comparison of metacognitive efficiency indices (Mratio) between social cognition tasks and memory tasks.

    Time frame: A single evaluation conducted between Day 1 and Day 20

  5. Effect of task complexity on metacognitive performance

    Comparison of metacognitive performance across tasks of varying complexity (low-level emotion recognition vs higher-level theory of mind).

    Time frame: A single evaluation conducted between Day 1 and Day 20

  6. Effect of feedback on metacognitive adjustment

    Evaluation of changes in metacognitive judgments following feedback on actual performance.

    Time frame: Day 0, with the second evaluation taking place between Day 1 and Day 20

  7. Subjective versus objective metacognitive assessment

    Comparison between questionnaire-based (subjective) and task-based (objective) metacognitive measures and their relationship with social cognition.

    Time frame: Day 0, with the second evaluation taking place between Day 1 and Day 20

  8. Impact of anosognosia on social cognition in Alzheimer's disease

    Comparison of social cognitive and metacognitive performance between Alzheimer's disease patients with and without anosognosia.

    Time frame: Day 0, with the second evaluation taking place between Day 1 and Day 20

  9. Association between hypnotic suggestibility and metacognition

    Exploration of the relationship between hypnotic suggestibility scores and metacognitive performance in bvFTD and AD patients.

    Time frame: A single optional evaluation conducted between Day 1 and Day 20

07

Study locations

1 of 1 sites recruiting
  • Cognitive Neurology Center, Lariboisière-Fernand Widal Hospital Group, APHP
    Paris, 75010, France
    Recruiting
08

References and documents

Publications

  • Mendez MF, Shapira JS. Loss of emotional insight in behavioral variant frontotemporal dementia or "frontal anosodiaphoria". Conscious Cogn. 2011 Dec;20(4):1690-6. doi: 10.1016/j.concog.2011.09.005. Epub 2011 Sep 29. PubMed 21959203 ↗
  • Caillaud M, Bejanin A, Laisney M, Gagnepain P, Gaubert M, Viard A, Clochon P, de La Sayette V, Allain P, Eustache F, Desgranges B. Influence of emotional complexity on the neural substrates of affective theory of mind. Hum Brain Mapp. 2020 Jan;41(1):139-149. doi: 10.1002/hbm.24794. Epub 2019 Sep 30. PubMed 31566290 ↗
  • Ebner NC, Riediger M, Lindenberger U. FACES--a database of facial expressions in young, middle-aged, and older women and men: development and validation. Behav Res Methods. 2010 Feb;42(1):351-62. doi: 10.3758/BRM.42.1.351. PubMed 20160315 ↗
  • Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R; Contributors. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018. PubMed 29653606 ↗
  • Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EG, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, Rankin KP, Johnson JK, Gorno-Tempini ML, Rosen H, Prioleau-Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN, Warren JD, Fox NC, Galasko D, Salmon DP, Black SE, Mesulam M, Weintraub S, Dickerson BC, Diehl-Schmid J, Pasquier F, Deramecourt V, Lebert F, Pijnenburg Y, Chow TW, Manes F, Grafman J, Cappa SF, Freedman M, Grossman M, Miller BL. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011 Sep;134(Pt 9):2456-77. doi: 10.1093/brain/awr179. Epub 2011 Aug 2. PubMed 21810890 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Dec 2027, 20 months later.

Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's planned 20 months is below that.

Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2026
First posted
Apr 15, 2026
StartEst.
Apr 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07531732
Collaborators
Institut de psychologie, Université Paris Cité, Laboratoire Mémoire, Cerveau, Cognition
Responsible party
Sponsor
First posted
Apr 15, 2026
Start date
Apr 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Apr 15, 2026

Study contacts

Emmanuel Cognat, MD PhD
Contact
emmanuel.cognat@aphp.fr
+33 (0) 1 40 05 49 54

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion